Regulatory Affairs and Regulatory Requirements for New Drug Approval

Abstract

Regulatory affairs is a growing field dedicated to ensuring the safety, quality, and efficacy of drug products through the submission of Investigational New Drug (IND) and New Drug Applications (NDA) to regulatory authorities. This process is critical for safeguarding public health by preventing the distribution of harmful or ineffective drugs. The primary goal of regulatory affairs professionals is to manage and oversee clinical and nonclinical trials, ensuring compliance with the necessary guidelines before a drug reaches the market. Different countries have varying regulatory requirements for marketing authorization, with each country’s regulatory authority responsible for enforcing these standards. In India, for example, the Central Drugs Standards Control Organization (CDSCO) is the key body responsible for approving new drugs. This review highlights the regulatory process for new drug approval in India, detailing the steps and documentation required for IND and NDA submissions. Furthermore, it discusses the importance of post-marketing surveillance (Phase IV) to monitor the long-term safety of approved drugs. The regulatory frameworks and processes, though similar in some respects, vary across regions like the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and CDSCO, with each playing a crucial role in the global drug approval landscape.